Body mass index and weight loss as risk factors for poor outcomes in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis

References

• Zheng Q, Cox IA, Campbell JA, et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 2022;8(1):1. 00591-2021. doi: 10.1183/23120541.00591-2021.
   Google Scholar
• Tseng CM, Chen MY, Kao CY, et al. Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: a cohort study in Taiwan. J Chin Med Assoc. 2022;85(5):578–10. doi: 10.1097/JCMA.0000000000000719.
   PubMed Web of Science ®Google Scholar
• Torrisi SE, Vancheri A, Pavone M, et al. Comorbidities of IPF: how do they impact on prognosis. Pulm Pharmacol Ther. 2018;53:6–11. doi: 10.1016/j.pupt.2018.09.003.
   PubMed Web of Science ®Google Scholar
• Jouneau S, Rousseau C, Lederlin M, et al. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin Nutr. 2022;41(6):1335–1342. doi: 10.1016/j.clnu.2022.05.001.
   PubMed Web of Science ®Google Scholar
• Jouneau S, Kerjouan M, Rousseau C, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition. 2019;62:115–121. doi: 10.1016/j.nut.2018.12.008.
   PubMed Web of Science ®Google Scholar
• Jouneau S, Crestani B, Thibault R, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020;21(1):312. doi: 10.1186/s12931-020-01528-4.
   PubMed Web of Science ®Google Scholar
• Jouneau S, Crestani B, Thibault R, et al. Post hoc analysis of clinical outcomes in placebo- and Pirfenidone-Treated patients with IPF stratified by BMI and weight loss. Respiration. 2022;101(2):142–154. doi: 10.1159/000518855.
   PubMedGoogle Scholar
• Zinellu A, Carru C, Pirina P, et al. A systematic review of the prognostic significance of the body mass index in idiopathic pulmonary fibrosis. J Clin Med. 2023;12(2):498. doi: 10.3390/jcm12020498.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. doi: 10.1164/rccm.201807-1255ST.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040GL.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic society (ATS), and the European respiratory society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–664.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi: 10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148–1157. doi: 10.1093/ije/dyn065.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463. doi: 10.1111/j.0006-341x.2000.00455.x.
   PubMed Web of Science ®Google Scholar
• Mochizuka Y, Suzuki Y, Kono M, et al. Geriatric nutritional risk index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis. Respirology. 2023;28(8):775–783. doi: 10.1111/resp.14523.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin YY, Kim HJ, et al. Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone. Sci Rep. 2022;12(1):17397. doi: 10.1038/s41598-022-22449-w.
   PubMed Web of Science ®Google Scholar
• Fujita K, Ohkubo H, Nakano A, et al. Decreased peak expiratory flow rate associated with mortality in idiopathic pulmonary fibrosis: a preliminary report. Chron Respir Dis. 2022;19:14799731221114153. doi: 10.1177/14799731221114153.
   Web of Science ®Google Scholar
• Zinellu A, Collu C, Zinellu E, et al. IC4: a new combined predictive index of mortality in idiopathic pulmonary fibrosis. Panminerva Med. 2022;64(2):228–234. doi: 10.23736/S0031-0808.21.04144-6.
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Nishiyama O, Yoshikawa K, et al. Outcome of patients who were incidentally diagnosed with idiopathic pulmonary fibrosis: how early in the disease should we identify patients? Respir Med. 2022;201:106933. doi: 10.1016/j.rmed.2022.106933.
   PubMed Web of Science ®Google Scholar
• Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the swedish IPF registry. Respir Res. 2021;22(1):40. doi: 10.1186/s12931-021-01634-x.
   PubMed Web of Science ®Google Scholar
• Kishaba T, Maeda A, Yamazato S, et al. Radiological and physiological predictors of IPF mortality. Medicina (Kaunas). 2021;57(10):1121. doi: 10.3390/medicina57101121.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Mori K, Aono Y, et al. Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Sci Rep. 2021;11(1):18579. doi: 10.1038/s41598-021-98161-y.
   PubMed Web of Science ®Google Scholar
• Zinellu A, Collu C, Nasser M, et al. The aggregate index of systemic inflammation (aisi): a novel prognostic biomarker in idiopathic pulmonary fibrosis. J Clin Med. 2021;10(18):4134. doi: 10.3390/jcm10184134.
   PubMed Web of Science ®Google Scholar
• Alhamad E, Cal J, Alrajhi N, et al. Acute exacerbation in interstitial lung disease. Ann Thorac Med. 2021;16(2):178–187. doi: 10.4103/atm.atm_14_21.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Aono Y, Kono M, et al. Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy. Respirology. 2021;26(2):171–179. doi: 10.1111/resp.13943.
   PubMed Web of Science ®Google Scholar
• Alhamad EH, Cal JG, Alrajhi NN, et al. Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis. Ann Thorac Med. 2020;15(4):208–214. doi: 10.4103/atm.ATM_230_20.
   PubMed Web of Science ®Google Scholar
• Lee SI, Chae EJ, Song JS, et al. Pleuroparenchymal fibroelastosis in patients with idiopathic pulmonary fibrosis. Respirology. 2020;25(10):1046–1052. doi: 10.1111/resp.13796.
   PubMed Web of Science ®Google Scholar
• Aono Y, Nakamura Y, Kono M, et al. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2020;14:1753466620953783. (doi: 10.1177/1753466620953783.
   Web of Science ®Google Scholar
• Enomoto N, Oyama Y, Yasui H, et al. Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep. 2019;9(1):10484. doi: 10.1038/s41598-019-46990-3.
   PubMedGoogle Scholar
• Snyder L, Neely ML, Hellkamp AS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO registry. Respir Res. 2019;20(1):105. doi: 10.1186/s12931-019-1043-9.
   PubMedGoogle Scholar
• Li B, Zhang X, Xu G, et al. Serum prealbumin is a prognostic indicator in idiopathic pulmonary fibrosis. Clin Respir J. 2019;13(8):493–498. doi: 10.1111/crj.13050.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Yoshimura K, Enomoto Y, et al. Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Sci Rep. 2018;8(1):14074. doi: 10.1038/s41598-018-32478-z.
   PubMedGoogle Scholar
• Serajeddini H, Rogliani P, Mura M. Multi-dimensional assessment of IPF across a wide range of disease severity. Lung. 2018;196(6):707–713. doi: 10.1007/s00408-018-0152-4.
   PubMed Web of Science ®Google Scholar
• Nishiyama O, Yamazaki R, Sano H, et al. Physical activity in daily life in patients with idiopathic pulmonary fibrosis. Respir Investig. 2018;56(1):57–63. doi: 10.1016/j.resinv.2017.09.004.
   PubMed Web of Science ®Google Scholar
• Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96(4):338–347. doi: 10.1159/000490355.
   PubMed Web of Science ®Google Scholar
• Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22(3):480–485. doi: 10.1111/resp.12941.
   PubMed Web of Science ®Google Scholar
• Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J. 2017;49(2):1601592. doi: 10.1183/13993003.01592-2016.
   PubMed Web of Science ®Google Scholar
• Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40(1):93–100. doi: 10.1183/09031936.00115511.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. SarcoidosVascul Diffuse Lung Dis. 2010;27(2):103–110.
   PubMed Web of Science ®Google Scholar
• Bonella F, Campo I, Zorzetto M, et al. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. Orphanet J Rare Dis. 2021;16(1):111. doi: 10.1186/s13023-021-01750-3.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Taniguchi H, Ebina M, et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis–extended analysis of pirfenidone trial in Japan. Respir Investig. 2015;53(6):271–278. doi: 10.1016/j.resinv.2015.04.005.
   PubMedGoogle Scholar
• Jalaber C, Lemerre-Poincloux J, Jouneau S, et al. Usefulness of body composition CT analysis in patients with idiopathic pulmonary fibrosis: a pilot study. Acad Radiol. 2022,292;29 Suppl 2(SI):S191–S201. doi: 10.1016/j.acra.2021.07.020.
   PubMedGoogle Scholar
• Kim HJ, Snyder LD, Adegunsoye A, et al. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):257. doi: 10.1186/s12931-021-01851-4.
   PubMedGoogle Scholar
• Kalininskiy A, Rackow AR, Nagel D, et al. Association between weight loss and mortality in idiopathic pulmonary fibrosis. Respir Res. 2022;23(1):377. doi: 10.1186/s12931-022-02277-2.
   PubMed Web of Science ®Google Scholar
• Lee JS, Martin-Schwarze A, Freiheit E, et al. Real-World clinical outcomes based on body mass index and annualized weight change in patients with idiopathic pulmonary fibrosis. Adv Ther. 2023;40(2):691–704. doi: 10.1007/s12325-022-02382-0.
   PubMed Web of Science ®Google Scholar
• Pedraza-Serrano F, Jimenez-Garcia R, Lopez-de-Andres A, et al. Comorbidities and risk of mortality among hospitalized patients with idiopathic pulmonary fibrosis in Spain from 2002 to 2014. Respir Med. 2018;138:137–143. doi: 10.1016/j.rmed.2018.04.005.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496–504. doi: 10.1183/09031936.00077309.
   PubMed Web of Science ®Google Scholar
• Balestro E, Cocconcelli E, Tinè M, et al. Idiopathic pulmonary fibrosis and lung transplantation: when it is feasible. Medicina (Kaunas). 2019;55(10):702. doi: 10.3390/medicina55100702.
   PubMed Web of Science ®Google Scholar
• Platenburg M, van Moorsel C, Wiertz IA, et al. Improved survival of IPF patients treated with antifibrotic drugs compared with untreated patients. Lung. 2023;201(4):335–343. doi: 10.1007/s00408-023-00628-4.
   PubMed Web of Science ®Google Scholar
• Faverio P, Bocchino M, Caminati A, et al. Nutrition in patients with idiopathic pulmonary fibrosis: critical issues analysis and future research directions. Nutrients. 2020;12(4):1131. doi: 10.3390/nu12041131.
   PubMed Web of Science ®Google Scholar
• Awano N, Jo T, Yasunaga H, et al. Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis. ERJ Open Res. 2021;7(2):00037-2021. 00037-2021. doi: 10.1183/23120541.00037-2021.
   PubMedGoogle Scholar
• Yang WS, Chang YC, Chang CH, et al. The association between body mass index and the risk of hospitalization and mortality due to infection: a prospective cohort study. Open Forum Infect Dis. 2021;8(1):a545.
   Web of Science ®Google Scholar
• Hisata S, Bando M, Homma S, et al. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan. Respir Investig. 2021;59(6):819–826. doi: 10.1016/j.resinv.2021.04.005.
   PubMed Web of Science ®Google Scholar
• Wasse LK, Sunderland C, King JA, et al. Influence of rest and exercise at a simulated altitude of 4,000 m on appetite, energy intake, and plasma concentrations of acylated ghrelin and peptide YY. J Appl Physiol (1985). 2012;112(4):552–559. doi: 10.1152/japplphysiol.00090.2011.
   PubMed Web of Science ®Google Scholar
• Singhal R, Shah YM. Oxygen battle in the gut: hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine. J Biol Chem. 2020;295(30):10493–10505. doi: 10.1074/jbc.REV120.011188.
   PubMed Web of Science ®Google Scholar
• Zinellu A, Fois AG, Pirina P, et al. A systematic review and meta-analysis of clinical, respiratory, and biochemical risk factors for acute exacerbation of idiopathic pulmonary fibrosis. Arch Med Res. 2023;54(4):319–331. doi: 10.1016/j.arcmed.2023.04.002.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–275. doi: 10.1164/rccm.201604-0801CI.
   PubMed Web of Science ®Google Scholar
• El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008;53(9):2307–2312. doi: 10.1007/s10620-008-0413-9.
   PubMed Web of Science ®Google Scholar
• Song Q, Zhou A, Lin L, et al. The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index. Front Pharmacol. 2023;14:1131614. doi: 10.3389/fphar.2023.1131614.
   PubMed Web of Science ®Google Scholar
• Liu J, Yuan M, Chen Y, et al. Global burden of asthma associated with high body mass index from 1990 to 2019. Ann Allergy Asthma Immunol. 2022;129(6):720–730.e8. doi: 10.1016/j.anai.2022.08.013.
   PubMed Web of Science ®Google Scholar
• Singh D, Oosterholt S, Pavord I, et al. Understanding the clinical implications of individual patient characteristics and treatment choice on the risk of exacerbation in asthma patients with moderate-Severe symptoms. Adv Ther, 10, 2023, 40:4606–4625. doi: 10.1007/s12325-023-02590-2.
   PubMed Web of Science ®Google Scholar